Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 29:4:213.
doi: 10.3389/fmed.2017.00213. eCollection 2017.

Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece

Argyrios Tzouvelekis  1   2 , Theodoros Karampitsakos  3 , Paschalis Ntolios  4 , Vasilios Tzilas  1 , Evangelos Bouros  1 , Evangelos Markozannes  1 , Ioanna Malliou  1 , Aris Anagnostopoulos  1 , Andreas Granitsas  1 , Paschalis Steiropoulos  2 , Katerina Dimakou  3 , Serafeim Chrysikos  4 , Nikolaos Koulouris  1 , Demosthenes Bouros  1
Affiliations

Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece

Argyrios Tzouvelekis et al. Front Med (Lausanne). .

Erratum in

Abstract

Background: Pirfenidone is an antifibrotic compound able to slow down disease progression in patients with idiopathic pulmonary fibrosis (IPF).

Objective: To investigate the safety and efficacy of pirfenidone in patients with IPF in a real-life setting.

Methods: This was a multicenter, retrospective, real-life, observational study for patients with IPF receiving pirfenidone.

Results: We identified 92 patients with IPF receiving pirfenidone. Eighty patients (70 males and 10 females, mean age ± SD: 68.1 + 7.5, mean %FVC ± SD = 74.9 ± 17.2, mean %DLCO ± SD = 48.1 ± 16.9) were included in the analysis. Skin-related (25%) and gastrointestinal (17.5%) adverse events were the most common and led to drug discontinuation in 22.5% of cases. The majority (87%) of patients experienced side effects during the first 6 months of treatment. At 36 months, changes in %FVC and %DLCO were -9.25 ± 16.34 and -9.26 ± 15.26, respectively. At 6, 12, and 24 months after treatment initiation (n = 80, 60, and 26), 18, 15, and 5 patients (22.5, 25, and 19.2%) experienced significant (>10%) and 11, 3, and 3 patients (13.8, 5, and 11.5%) experienced marginal (5-10%) %FVC improvement; and 13, 6, and 1 patient (16.2, 10, and 3.9%) experienced marginal (-5 to -10%) and 20, 21, and 8 patients (25, 35, and 30.8%) experienced significant decline (<-10%) in %FVCpred. Median survival was 851 days, and 41 patients died during the study period.

Conclusion: Pirfenidone demonstrated an acceptable safety and therapeutic profile in patients with IPF on a longitudinal basis. Prospective observational registries are urgently needed to provide a real-world view of outcomes of pirfenidone in clinical practice.

Keywords: efficacy; idiopathic pulmonary fibrosis; pirfenidone; safety; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in %forced vital capacity (ΔFVC) as %predicted ± SD, at different time points following pirfenidone treatment. Time 0 denotes the onset of treatment. Deaths were treated as censored. One-way ANOVA, p < 0.05.
Figure 2
Figure 2
Changes in %diffusion capacity of lung for carbon monoxide (ΔDLCO) as %predicted ± SD, at different time points following pirfenidone treatment. Time 0 denotes the onset of treatment. Deaths were treated as censored. One-way ANOVA, p < 0.05.
Figure 3
Figure 3
Percentage of patients with IPF experiencing significant (>10%) or marginal (5–10%) improvement, stability (−5 to 5%), and marginal (−5 to −10%) or significant (<−10%) decline in %forced vital capacity (%ΔFVC) at different time points (6, 12, 24, and 36 months) following pirfenidone treatment. Note that 65% of patients experienced disease stability after 24 months of treatment.
See this image and copyright information in PMC

References

    1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 183:788–824.10.1164/rccm.2009-040GL - DOI - PMC - PubMed
    1. Karampitsakos T, Tzilas V, Tringidou R, Steiropoulos P, Aidinis V, Papiris SA, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther (2017) 45:1–1010.1016/j.pupt.2017.03.016 - DOI - PubMed
    1. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev (2012) 21:355–61.10.1183/09059180.00002512 - DOI - PMC - PubMed
    1. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2006) 174:810–6.10.1164/rccm.200602-163OC - DOI - PubMed
    1. Bouros D, Tzouvelekis A. Idiopathic pulmonary fibrosis: on the move. Lancet Respir Med (2014) 2:17–9.10.1016/S2213-2600(13)70240-6 - DOI - PubMed

LinkOut - more resources